GNT Pharma Signs Technology Transfer and Manufacturing Agreement for "Jedacure" with Chanel Pharma

by Jeong Donghoon

Published 10 Nov.2025 09:15(KST)

GNT Pharma, a new drug development venture company, announced on November 10 that it has signed a strategic agreement with Chanel Pharma, the largest animal pharmaceutical manufacturer in Ireland, for the global regulatory approval and launch of Jedacure, a treatment for canine cognitive dysfunction.

On the 7th, Gwak Byungju, CEO of GNT Pharma (left), and Angelo Cato, CEO of Chanel Pharma, are holding the contract for the global launch of Jedacure and taking a commemorative photo. GNT Pharma

Chanel Pharma is a global CDMO (Contract Development and Manufacturing Organization) that holds more than 3,500 animal pharmaceutical licenses, the highest number among European countries, and exports to over 80 countries worldwide. Under this agreement, Chanel Pharma will invest significant resources in its state-of-the-art production facility in Loughrea, Ireland, to establish a dedicated manufacturing line for Jedacure to obtain regulatory approvals in the United States and Europe. The company will complete production and stability studies for Jedacure by the second quarter of 2027.

GNT Pharma has been pursuing overseas technology transfers for Jedacure, and plans to begin regulatory approval and sales in collaboration with additional technology transfer partners as soon as Chanel Pharma’s cGMP (current Good Manufacturing Practice) production facility is completed. Having signed its first technology transfer agreement in Europe, Chanel Pharma will have exclusive sales rights for Jedacure in the United Kingdom and Ireland.

Jedacure is a synthetic new animal drug that was the first of its kind to be approved in Korea in February 2021, having demonstrated efficacy and safety in dogs suffering from cognitive dysfunction similar to Alzheimer’s disease in humans. Post-marketing studies have reported long-term efficacy of Jedacure, as well as its effects in treating arthritis and pain, and the indication is being expanded to cats.

GNT Pharma stated, “As the population of aging companion dogs increases, veterinary awareness of cognitive dysfunction is spreading rapidly. We expect Jedacure to become a game-changer in the global market for geriatric canine pharmaceuticals.” The company added that the completion of Jedacure’s European patent registration in September has further solidified its global intellectual property foundation.

JNTPharma's treatment for canine cognitive dysfunction, Jedacure. JNTPharma

Gwak Byungju, CEO of GNT Pharma and adjunct professor at Yonsei University’s Department of Life Sciences, said, “Jedacure is the world’s first dual-pharmacology new drug for senior dogs experiencing cognitive decline. Clinical trials and four years of post-marketing studies have proven its significant symptom improvement and disease treatment effects in not only early and middle stages but also late-stage canine dementia, all while maintaining a strong safety profile. Our collaboration with Chanel Pharma, which possesses global-level quality and regulatory capabilities, will allow us to rapidly advance Jedacure’s global regulatory approval and launch.”

Angelo Cato, CEO of Chanel Pharma, stated, “We are very proud to support entry into the European and global markets through our partnership with GNT Pharma, which has developed an innovative drug in the companion animal field. This agreement will further strengthen our position as a global leader in animal pharmaceutical CDMO and open new horizons in the treatment of cognitive dysfunction in companion animals.”

According to global digital platforms such as the World Animal Foundation (WAF), there are currently 470 million companion dogs worldwide, and it is estimated that 4% of them, or 18.8 million, suffer from cognitive dysfunction. The domestic market for Jedacure has been growing rapidly since its launch, with sales projected to reach 6.2 billion won by 2030.

GNT Pharma stated, “Given that the domestic companion animal pharmaceutical market accounts for only 0.5% of the global market, Jedacure’s global sales are expected to exceed 300 billion won, making it likely to become Korea’s first blockbuster new animal drug.”